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Abstract
Purpose In this study, we evaluated C-reactive protein
(CRP), interleukin (IL)-8, procalcitonin (PCT), and soluble
triggering receptor expressed on myeloid cells-1 (sTREM-
1) as predictors for bacterial infection in febrile neutropenia,
plus their usefulness in febrile neutropenia during
chemotherapy-induced gastrointestinal mucositis.
Methods Plasma was obtained from pediatric oncology
patients at presentation with febrile neutropenia (n=43)
and 24–48 h later (n=17). The patients were classified as
having or not having a bacterial infection. Plasma was also
obtained of patients in the absence and in the presence of
mucositis (n=26).
Results At presentation with febrile neutropenia, median
IL-8 and PCT levels were significantly increased in patients
with a bacterial infection, in contrast to CRP and sTREM-1.
IL-8 was the most sensitive marker for the early detection
of bacterial infection, in combination with clinical param-
eters or PCT the sensitivity reached 100%. After 24–48 h,
only PCT was significantly elevated during bacterial
infection. IL-8 levels were significantly increased during
mucositis. Mucositis did not cause considerable changes in
PCT levels.
Conclusions IL-8 is the most useful marker for the early
detection of bacterial infections, compared with CRP, PCT,
and sTREM-1. IL-8 in combination with clinical parame-
ters or PCT might be even more useful. Gastrointestinal
mucositis alone does not affect PCT levels, in contrast to
IL-8 levels, and therefore, PCT might be more useful for
the detection of bacterial infections during mucositis than
IL-8.
Keywords Febrile neutropenia.Bacterial infection.
Biomarkers.Children.Mucositis
Introduction
Infectious complications in pediatric oncology patients
are a major cause of morbidity and mortality. The risk of
infections is particularly high during neutropenia, which is
defined as an absolute neutrophil count (ANC) less than
0.5×10
9/L [1]. Fever during chemotherapy-induced neu-
tropenia may be the first an do n l ys i g no fb a c t e r i a l
infection, especially in children [2]. Therefore, standard
care for patients with febrile neutropenia consists of routine
hospitalization and empirical treatment with intravenous
broad-spectrum antibiotics. Guidelines recommend that
patients should not be discharged until they are afebrile
for at least 24 h and the ANC has recovered [3]. However,
in only 20–30% of the children an actual bacterial infection
is documented during febrile neutropenia [2, 4–6]. In the
majority of patients, fever has other causes, like viral or
fungal infections, the malignancy itself, mucositis, drugs, or
transfusions of blood products; all causes that do not
require antibiotics. Yet there is no generally accepted
method which can rapidly differentiate between patients
with febrile neutropenia who are at high risk for bacterial
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DOI 10.1007/s00520-010-0987-6infection, thus needing antibiotics, and in whom antibiotics
can be withheld.
In the past decades, there have been many studies
examining risk factors to assess the risk of having
bacteremia or a severe bacterial infection during febrile
neutropenia, such as indwelling central venous catheters,
relapsed malignancy, comorbidity, hypotension, and several
biomarkers [7–12]. The most widely used biomarker as diag-
nostic indicator is C-reactive protein (CRP). Unfortunately,
CRP levels do not increase significantly until 24–48 h after
onset of inflammation, and its specificity and positive
predictive value are low [13–15].
Another inflammatory marker is interleukin 8 (IL-8).
IL-8 is a cytokine with powerful chemotactic activity for
neutrophils. IL-8 is released from monocytes, endothelial
cells,and many other cells,inresponsetointerleukin 1 (IL-1),
tumor necrosis factor (TNF), and lipopolysaccharide (LPS)
[16]. IL-8 levels have been shown to increase much earlier
than CRP levels—increasing levels of IL-8 can frequently be
detected even before onset of fever [17, 18]. Furthermore,
we have shown previously in a group of pediatric and adult
patients that withholding antibiotics in low-risk patients,
whichisdefinedbyIL-8incombinationwithclinicalparameters,
is feasible [4].
Procalcitonin (PCT) was described as a new and
innovative marker for infection for the first time in 1993
[19]. Inducers of PCT are bacterial endotoxins and exotoxins,
as well as inflammatory cytokines, e.g., TNF, IL-2, and IL-6
[20]. During bacterial infections, levels of PCT reach plateau
values within 8–24 h [21, 22]. It was recently suggested that
monitoring PCT levels could be a valuable tool for guiding
antibiotic treatment in nonneutropenic patients in an intensive
care unit [23].
A recently discovered inflammatory marker is the
soluble triggering receptor expressed on myeloid cells-1
(sTREM-1). sTREM-1 has been identified on neutrophils,
mature monocytes, and macrophages, and is upregulated
by LPS, bacteria, and fungi [24]. The predictive value of
sTREM-1 for the presence of bacterial infections is question-
able [25–28]. sTREM-1 has not been studied in neutropenic
patients before.
Despite the fact that CRP is currently widely used as
marker for bacterial infection, it has several major disadvan-
tages, such as its delayed increase and low specificity.
However, IL-8, PCT, and sTREM-1 have not been character-
ized well enough to know whether they could replace or
supplement the use of CRP, or whether they can be of use in
determining patients in whom antibiotics can be withheld
or stopped early. Therefore, in this study we examined CRP,
IL-8, PCT, and sTREM-1, separately and in combination, as
early and late detectors for bacterial infection in pediatric
oncology patients with febrile neutropenia.
In addition,we examined the markers during chemotherapy-
induced mucositis, an inflammatory process of the gastrointes-
tinal tract. Mucositis can be complicated by bacterial infections,
e.g. Streptococcus viridans bacteremia or Clostridium difficile
enterocolitis, but in most cases, mucositis only exists of an
inflammatory component. Like bacterial infections, inflamma-
tory mucositis can also cause fever, but does not require
antibiotic treatment. Therefore, it is imperative to determine
whether CRP, IL-8, PCT, and sTREM-1 can distinguish fever
caused by mucositis from fever caused by bacterial infections.
Methods
Patient characteristics
Febrile neutropenia All pediatric oncology patients treated
with chemotherapy from April 1999 to August 2002 at the
Department of Pediatric Oncology and Haematology at the
University Medical Centre of Groningen, the Netherlands,
were asked to participate in a prospective study on febrile
neutropenia [4]. Clinical data were collected of all patients
from their patient charts. Neutropenia was defined as ANC
less than 0.5×10
9/L and/or leukocytes less than 1.0×10
9/L.
Fever was defined as a single body temperature reading
higher than 38.5°C, or two or more recordings of a body
temperature higher than 38.0°C during a 6-h period.
Plasma was collected during each febrile neutropenic
episode at presentation with febrile neutropenia, and after
24–48 h. Patients were divided into two groups, with or
without bacterial infection/clinical sepsis. Bacterial infec-
tion was proven or suspected, as defined by either the
growth of a known pathogen from culture of fluid collected
from an otherwise sterile site, radiologically confirmed
pneumonia or sinusitis, or abnormal vital signs suggesting
clinicalsepsis,e.g.,hypotensionortachycardia andtachypnea
(‘abnormal’ defined as more than two standard deviations
above or below normal, corrected for age and sex).
Mucositis Mucositis was studied using blood samples
drawn in a former study of pediatric patients newly
diagnosed with acute myeloid leukemia at the University
Medical Centre of Groningen between October 2005 and
October 2006 [29], who were receiving chemotherapy
likely to cause mucositis. Plasma was collected at two time
points. The first sample was collected at the start of
chemotherapy (range, −1–5 days), before developing
mucositis. The second sample was collected at day 12 of
chemotherapy (range, 7–17 days) during periods of
chemotherapy-induced mucositis. Mucositis was confirmed
by gastrointestinal symptoms (diarrhea, abdominal pain,
and/or nausea/vomiting) and the plasma citrulline level.
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CRP was measured turbidimetrically using the Hitachi 917
analytic device and reagents of Roche Diagnostics. This
method has a lower detection limit of 5 mg/l. IL-8 was
measured using the solid-phase, two-site chemiluminescent
immunometric assay. IL-8 was performed fully automated
on the IMMULITE 1000. The lower detection limit of the
assay is 5 ng/l. Plasma concentrations of PCT were
determined in duplicate by an enzyme-linked fluorescent
immunoassay (VIDAS B.R.A.H.M.S PCT, provided by
Biomérieux), and reported levels represent the mean of
these values. The lower detection limit is 0.05 ng/ml.
sTREM-1 was measured using an ELISA assay. The
plasma samples were diluted 4 times. The lower detection
level is 7 pg/ml. sTREM-1 determinations below the
detection limit are shown in the figures as 7 pg/ml.
Statistical analysis
Descriptive statistics were reported in terms of absolute
frequencies and percentages. Distribution of data regarding
febrile neutropenic episodes were described in terms of a
median value and range, because of the nonnormal distribu-
tionofthesevalues.Accordingly,comparisonbetweengroups
was performed using the nonparametric Mann–Whitney
U test (for unpaired samples) or Wilcoxon signed-rank test
(for paired samples). Associations were considered statisti-
cally significant with a p value<0.05. Data were calculated
for sensitivity and specificity, derived from receiver operat-
ing characteristics (ROC) curve. The commercial statistical
software package used was Statistical Package for the Social
Sciences 16.0 (SPSS, Chicago, IL).
Results
A total of 43 febrile neutropenic episodes in 29 patients
were enrolled in the study. In 17 of the 43 febrile
neutropenic episodes, plasma was also collected 24–48h
after presentation with febrile neutropenia. Eleven patients
were enrolled more than once. In 14 of the 43 febrile
neutropenic episodes a bacterial infection (proven or
suspected) was documented (32.6%), by positive blood
cultures (one Escherichia coli, one Klebsiella pneumoniae
and three Streptococcus mitis), abnormal vital signs (n=7),
urinary tract infections (n=2), radiographically confirmed
pneumonia (n=1), radiographically confirmed sinusitis
(n=1), or a panaritium (n=1). The clinical data of the 43
febrile neutropenic episodes and 29 patients are shown in
Table 1. No significant differences were found between the
groups, although the type of cancer (p=0.062) probably
would have been significant if the group of patients had
been larger.
The influence of mucositis on the levels of CRP, IL-8,
PCT and sTREM-1 was studied in a total of 26 episodes in
eight patients in the presence and in the absence of
mucositis. Five of the eight patients were female (63%).
The age of the included patients ranged from one to
15 years. Four patients developed fever during the presence
of mucositis. None of the patients with mucositis had a
bacterial infection. The median leukocyte count, ANC, and
the plasma citrulline level in the presence and absence of
mucositis are shown in Table 2.
Comparison of variables between patients with and without
bacterial infection Figure 1 shows the inflammatory
markers in infected and noninfected patients at presentation
Bacterial infection No bacterial infection P value
Number 14 29
Sex—no. (%)
Female 9 (64%) 12 (41%)
Male 5 (36%) 17 (59%) 0.164
Age—years
Median (interquartile range) 8 (6–13) 8 (6–12) 0.845
Type of cancer—no. (%)
Hematological malignancy 11 (79%) 14 (48%)
Solid tumor 3 (21%) 15 (52%) 0.062
Leukocytes at admission (×10
9/L)
Median (range) 0.25 (0.00–1.6) 0.4 (0.01–4.2) 0.252
ANC at admission (×10
9/L)
Median (range) 0.03 (0.02–0.04) 0.06 (0.00–0.67) 0.381
Table 1 Characteristics of
the febrile neutropenia study
population
ANC absolute neutrophil count
Support Care Cancer (2011) 19:1593–1600 1595with febrile neutropenia. Median IL-8 and PCT levels were
significantly higher in patients with bacterial infection
compared with patients without bacterial infection (318.5 vs
55 ng/l, p=0.002; 0.81 vs 0.10 ng/ml, p=0.001, respectively),
at presentation with febrile neutropenia. Median CRP levels
did not differ significantly (64 vs 32 mg/l, p=0.183).sTREM-
1 levels were below the detection limit in 33 patients, and
therefore excluded from further analyses.
Twenty-four to forty-eight hours after presentation with
febrile neutropenia, mean PCT levels were significantly
elevated in patients with bacterial infection compared with
patients without bacterial infection (2.01 vs 0.22 ng/ml,
p=0.047). At this time point, no significant differences
were documented in median CRP and IL-8 levels between
patients with and without bacterial infection.
ROC curves were generated for CRP, IL-8, and PCT at
admission with febrile neutropenia (Fig. 2). The area under
the curve demonstrated good individual discriminatory power
forIL-8andPCT(0.810,95%CI0.656–0.965;0.769,95%CI
0.612–0.925, respectively). CRP demonstrated poor discrim-
inatory power (0.596, 95% CI 0.388–0.803).
Table 3 shows the sensitivity and specificity for CRP,
IL-8, and PCT at presentation with febrile neutropenia and
24–48 h later, at cut-off values of 40 mg/l for CRP, 60 ng/l for
IL-8, and 0.25 ng/ml for PCT. These cut-off values were
chosen based on the best sensitivity and specificity (data not
shown), and according to the literature. IL-8 showed the
highest sensitivity (92%) compared with PCT and CRP
(sensitivity 79% and 69%, respectively). The analyses were
continued by constructing combinations between CRP, IL-8,
and PCT, and evaluating their values in the distinction
between bacterial infection and other causes of fever. IL-8 in
combination with PCT documented the most sensitive and
specific results. The sensitivity for this combination was
100%, whereas specificity was 52%. Table 4 shows the
p values, sensitivity and specificity of the combinations of
the biomarkers.
Comparison of variables in the presence and absence of
gastrointestinal mucositis To study whether the markers
could be useful as predictors for bacterial infection during
chemotherapy-induced mucositis, we examined the behav-
ior of the various markers during gastrointestinal mucositis.
Mucositis did not cause considerable changes in PCT levels
andCRP levels (0.06ng/ml vs 0.06 ng/ml, p=0.709;8mg/lvs
Table 2 Characteristics of the mucositis study population
No mucositis Mucositis P value
Number 26 26
Leukocyte count (×10
9/L)
Median (range) 3.7 (0.6–24.6) 0.55 (0.2–6.3) 0.001
ANC (×10
9/L)
a
Median (range) 1.6 (0.2–3.2) 0.05 (0.05–5.74) 0.075
Citrulline (μmol/L)
Median (range) 17 (5.3–29.4) 5.0 (1–14.5) <0.00001
ANC absolute neutrophil count
aThe ANC was often too low to measure (in these cases they were
regarded as 0.05×10
9/L), or not measured at all during mucositis
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Fig. 1 CRP, IL-8, PCT, and
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febrile neutropenia in patients
with and without bacterial
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represent the median. sTREM-1
is shown by log 10 at the y-axis,
because of the widespread
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1596 Support Care Cancer (2011) 19:1593–16005m g / l ,p=0.182, respectively). In contrast, the levels of IL-
8 were significantly increased during mucositis (52.4 ng/l vs
5.17 ng/l, p<0.01). sTREM-1 levels were below the detection
limit in 35 cases, and therefore excluded from analysis.
Figure 3 shows CRP, IL-8, PCT, and sTREM-1 in patients
with and without mucositis.
Discussion
In pediatric oncology patients with febrile neutropenia,
there is a need for markers that can determine which
patients are at high risk for bacterial infection and need
antibiotics, and in whom antibiotics can be withheld. In this
study we showed that CRP, which is widely used as
detector for bacterial infections, is actually a poor discrim-
inatory marker. IL-8 is more useful as marker for the early
detection of bacterial infections, and IL-8 in combination
with clinical parameters or PCT might be even more useful.
Gastrointestinal mucositis alone does not affect PCT levels,
in contrast to IL-8 levels, and therefore, PCT might be more
useful for the detection of bacterial infections during
mucositis than IL-8. Furthermore, we suggest the additional
use of PCT to define patients in whom antibiotics can be
stopped early.
Many studies have examined biochemical markers for
the detection of bacterial infections. Most studies have been
performed in nonneutropenic, adult patients. Nevertheless,
a number of studies have suggested that neutropenic
pediatric patients can produce a sufficient inflammatory
response to release CRP, IL-8, and PCT [7, 17, 30–32].
These results are in line with our findings. Whether
neutropenic children or adults can produce a sufficient
release of sTREM-1 in response to infection has by our
knowledge not yet been studied.
CRP, which is commonly used in practice, was shown in
this study to be a poor tool for distinguishing bacterial
infection from other causes of fever, given its low
sensitivity and specificity (69% and 62%, respectively).
According to our results, IL-8 is the best marker for the
early detection of bacterial infection. The sensitivity at
admission with febrile neutropenia was shown to be
respectably high (92%). High sensitivity is an essential
quality for a marker in order to be valuable in the selection
of patients in whom antibiotics can safely be withheld. In
the case of IL-8, only one patient with a bacterial infection
had IL-8 levels below the cut-off value of 60 ng/l. This
patientwas classifiedas havinga bacterialinfectionbecause of
clinicalsigns of sepsis (tachypneaand tachycardia). Therefore,
combining IL-8 and clinical parameters (blood pressure,
heart rate, and respiratory rate) could allow an increase in the
sensitivityupto100%,asstatedbyOudeNijhuiset al.[4]. Our
findings are comparable to those of others [31, 33].
Fleischhack and her colleagues [31] suggested that PCT
may be a more useful diagnostic inflammatory parameter
than CRP, IL-6, IL-8, sIL-2, and sTNFRII in neutropenic
pediatric cancer patients, but they chose Gram-negative
bacteraemia and fever of unknown origin as primary endpoints,
w h e r ew ew a n t e dt of i n dm a r k e rs to distinguish bacterial
infection from other causes of fever. In our study, the
sensitivity of PCT at presentation with febrile neutropenia
Fig. 2 ROC-curve for CRP, IL-8, and PCTat presentation with febrile
neutropenia
Table 3 Sensitivity and specificity for CRP, IL-8, and PCTat presentation of febrile neutropenia (t=0) and after 24–48 h (t=24–48) to distinguish
bacterial infection from other causes of fever
AUC (95% CI) Cut-off Sensitivity (t=0) Specificity (t=0) Sensitivity (t=24–48) Specificity (t=24–48)
CRP 0.609 (0.392–0.826) 40 mg/l 69% 62% 100% 42%
IL-8 0.807 (0.644–0.970) 60 ng/l 92% 54% 100% 57%
PCT 0.840 (0.710–0.970) 0.25 ng/ml 79% 77% 100% 53%
AUC area under the curve; CI confidence interval
Support Care Cancer (2011) 19:1593–1600 1597was only 79%. Therefore, PCT alone might not be useful in
the early detection of infection. However, 24–48 h after
presentation with febrile neutropenia, PCT is significantly
elevated in patients with a bacterial infection. Thus, PCT is a
relatively late marker and might be of value in identifying
patients in whom antibiotics can be stopped early. This is in
line with data suggesting that serial measurements of PCT
levels might help guiding antibiotic treatment in septic,
nonneutropenic adult patients [23, 34].
sTREM-1 has recently been suggested as a marker for
bacterial infection [24, 26, 28], but had not been studied
before in neutropenic patients. It is known that sTREM-1 is
expressed mainly on neutrophils and monocytes, when
triggered by bacteria. We studied whether there is an
increase of sTREM-1 levels during bacterial infections in
neutropenic patients, who might have enough monocytes to
produce measurable sTREM-1 levels. However, our results
showed that sTREM-1 is not usable as a marker in this
patient population. In our study only one patient had high
sTREM-1 levels (997 pg/ml). This patient in fact did have
a normal number of monocytes, which was 0.64×10
9/l
(normal levels, 0.3–1.3×10
9/l), while the ANC was no more
than 0.04×10
9/l. In all other patients both the number of
monocytes and the ANC were low (data not shown), which
could explain the low sTREM-1 levels in the infected
patients.
The best combination of markers for identifying bacterial
infections in febrile neutropenic patients appears to be
IL-8 and PCT. This combination results in a sensitivity of
100% in our patient population, and therefore seems to be
the optimal combination for the early detection of bacterial
infection.
In addition, we examined the various markers during
gastrointestinal mucositis, since mucositis is a commonly
seen phenomenon in pediatric oncology patients, causing
fever, but not requiring antibiotic treatment. As we have
shown before [29], IL-8 was elevated during mucositis,
even though patients did not suffer from a bacterial
infection. It thus seems that IL-8 is not useful as a marker
for bacterial infection in patients with mucositis. Our results
Table 4 Comparison of combinations of IL-8, PCT, and CRP, and their sensitivity and specificity in distinguishing bacterial infection from other
causes of fever at presentation with febrile neutropenia
Bacterial infection No bacterial infection P value Sensitivity Specificity
IL-8>60 and/or PCT>0.25 14/14 14/29 0.001 100% 52%
IL-8>60 and/or CRP>40 12/13 17/28 0.041 92% 39%
PCT>0.25 and/or CRP>40 13/14 15/29 0.016 93% 48%
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patients [35]. In contrast, other authors showed no increase
of IL-8 in response to mucositis [31, 36]. Our results further
showed that CRP and PCT levels are not significantly
influenced by mucositis. This is comparable to the results
of Fleischhack et al. [31]. On the other hand, there are some
studies that have documented a rise of CRP levels in
response to mucositis [35, 37]. Future studies have to
elucidate whether PCT is usable as marker for bacterial
infection during chemotherapy-induced gastrointestinal
mucositis in patients with a bacterial infection during
mucositis.
sTREM-1 had not yet been studied as a marker for
bacterial infection during mucositis. However, patients
develop chemotherapy-induced gastrointestinal mucositis
in the same period as they develop chemotherapy-induced
neutropenia. In line with the results of neutropenic fever,
we showed that sTREM-1 is not elevated during mucositis.
One might argue that the definition we used to ascertain
mucositis is questionable. The golden standard for measur-
ing gastrointestinal mucositis actually is a small intestine
biopsy. However, this method is not feasible in (pediatric)
patients, especially during neutropenia, which most often
accompanies mucositis. Other well-known methods for the
detection of mucositis are the NCI Common Terminology
Criteria for Adverse Events Score and the Daily Gut Score.
However, these methods both include fecal incontinence,
which occurs physiologically in young children and in
older ill children as a sign of regression. Therefore, we used
a less invasive, good alternative method for the detection of
gastrointestinal mucositis in children, which consists of the
combination of presence of gastrointestinal symptoms, such
as diarrhea, abdominal pain, and/or nausea/vomiting (as is
used by the NCI and the Daily Gut Score) and the plasma
citrulline level. Citrulline is a marker for enterocytic cell
loss, and has been shown to be a good clinical biomarker
for measuring and monitoring gastrointestinal mucositis
[29, 38].
Of course, the number of patients in this study was
small. Larger prospective studies are needed to establish the
value of IL-8 in determining patients in whom antibiotics
can be withheld. In fact, we are currently studying a risk
model for febrile neutropenic pediatric patients, based on
IL-8 and clinical parameters, in a multicenter setting, as was
proposed by Oude Nijhuis et al. [4].
In conclusion, IL-8 seems to be the best marker for the
early detection of bacterial infections in pediatric oncology
patients with febrile neutropenia. In combination with
clinical parameters, the sensitivity might be able to reach
even 100%, therefore this combination seems to be the
perfect tool in defining which febrile neutropenic patients
are at high risk of bacterial infection and need antibiotics,
and in whom antibiotics can be withheld. PCT might be of
additive value in identifying patients in whom antibiotics
can be stopped early, and during gastrointestinal mucositis.
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